Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock Sells 5,500 Shares

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $5.64, for a total transaction of $31,020.00. Following the completion of the sale, the executive vice president now owns 10,000 shares in the company, valued at $56,400. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Ted Yednock also recently made the following trade(s):

• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.95, for a total transaction of $32,725.00.

Annexon Trading Down 1.2 %

Shares of NASDAQ:ANNX opened at $5.75 on Friday. The business has a fifty day simple moving average of $5.68 and a 200 day simple moving average of $5.48. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40. The firm has a market cap of $531.37 million, a price-to-earnings ratio of -3.91 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). On average, sell-side analysts forecast that Annexon, Inc. will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Annexon

A number of large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its stake in shares of Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after acquiring an additional 2,949 shares in the last quarter. Comerica Bank bought a new stake in Annexon during the first quarter worth approximately $72,000. Sandia Investment Management LP acquired a new position in Annexon during the second quarter valued at approximately $49,000. Victory Capital Management Inc. bought a new position in shares of Annexon in the second quarter valued at approximately $51,000. Finally, Principal Financial Group Inc. bought a new position in shares of Annexon in the second quarter valued at approximately $56,000.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANNX. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Wednesday, June 5th. Finally, Wells Fargo & Company cut their price target on shares of Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.